Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.48 |
| ▸ | CA2 | P00918 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | CA5A | P35218 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424526 | 0.98 | — | — | |
| SCHEMBL2420634 | 0.84 | CA1 (0.58) | CA1CA2ALDH1A1CA12CA14 | |
| SCHEMBL21187939 | 0.75 | — | — | |
| SCHEMBL48193 | 0.75 | — | — | |
| SCHEMBL13103823 | 0.74 | ALDH1A1 (0.44) | CA2ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL18028390 | 0.74 | CA1 (0.46) | CA1CA2CA12CA14CA9 | |
| SCHEMBL2419870 | 0.74 | CA2 (0.52) | CA1CA2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5664577 | 0.73 | — | — | |
| SCHEMBL1146102 | 0.73 | CA2 (0.52) | CA1CA2CA12CA14CA9 | |
| SCHEMBL4424482 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569914-B1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-18 | — | — | EP | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1569914-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | Actelion Pharmaceuticals Ltd. (CH) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050640-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | EDNRA, EDNRB, AGTR2 | CA1 4312/4885CA2 1164/4885ALDH1A1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.